Page 895 - Read Online

Cullen et al. Hepatoma Res 2020;6:76 I http://dx.doi.org/10.20517/2394-5079.2020.69 Page 13 of 14

27. Kornberg A, Schernhammer M, Kornberg J, Friess H, Thrum K. Serological risk index based on alpha-fetoprotein and C-reactive protein
to indicate futile liver transplantation among patients with advanced hepatocellular carcinoma. Dig Dis Sci 2019;64:269-80.
28. Lee HW, Song GW, Lee SG, et al. Patient selection by tumor markers in liver transplantation for advanced hepatocellular carcinoma.
Liver Transpl 2018;24:1243-51.
29. Lin CC, Chen CL. Living donor liver transplantation for hepatocellular carcinoma achieves better outcomes. HepatoBiliary Surg Nutr
2016;5:415-21.
30. Lin C, Elsarawy AMAA, Chen C. Living donor liver transplantation for hepatocellular carcinoma. In: Abdeldayem HM, editor. InTech;
2017.
31. Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol
2006;12:7561-7.
32. Lee YH, Hsu CY, Huang YH, et al. Vascular invasion in hepatocellular carcinoma: prevalence, determinants and prognostic impact. J Clin
Gastroenterol 2014;48:734-41.
33. Chen ZH, Zhang XP, Lu YG, et al. Actual long-term survival in HCC patients with portal vein tumor thrombus after liver resection: a
nationwide study. Hepatol Int; 2020.
34. Cheng S, Yang J, Shen F, et al. Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - Eastern
Hepatobiliary Surgical Hospital consensus statement. Oncotarget 2016;7:40816-29.
35. Cerrito L, Annicchiarico BE, Iezzi R, et al. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond
the known frontiers. World J Gastroenterol 2019;25:4360-82.
36. Choi HJ, Kim DG, Na GH, et al. The clinical outcomes of patients with portal vein tumor thrombi after living donor liver transplantation.
Liver Transpl 2017;23:1023-31.
37. Shi J, Lai EC, Li N, et al. A new classification for hepatocellular carcinoma with portal vein tumor thrombus. J Hepatobiliary Pancreat
Sci 2011;18:74-80.
38. Peng SY, Wang XA, Huang CY, et al. Better surgical treatment method for hepatocellular carcinoma with portal vein tumor thrombus.
World J Gastroenterol 2018;24:4527-35.
39. Huo L, Wei W, Yan Z, et al. Short-term and long-term outcomes of liver resection for HCC patients with portal vein tumor thrombus. Cell
Biosci 2019;9:23.
40. Cheng S, Chen M, Cai J; National Research Cooperative Group for Diagnosis and Treatment of Hepatocellular Carcinoma with Tumor
Thrombus. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor
thrombus: 2016 edition. Oncotarget 2017;8:8867-76.
41. Moriguchi M, Furuta M, Itoh Y. A review of non-operative treatments for hepatocellular carcinoma with advanced portal vein tumor
thrombus. J Clin Transl Hepatol 2017;5:177-83.
42. Soin AS, Bhangui P, Kataria T, et al. Experience with LDLT in patients with hepatocellular carcinoma and portal vein tumor thrombosis
postdownstaging. Transplantation 2020; doi: 10.1097/TP.0000000000003162.
43. Lee KW, Suh SW, Choi YR, et al. Macrovascular invasion is not an absolute contraindication for living donor liver transplantation. Liver
Transplant 2017;23:19-27.
44. Toso C, Mentha G, Kneteman NM, Majno P. The place of downstaging for hepatocellular carcinoma. J Hepatol 2010;52:930–6.
45. Akateh C, Black SM, Conteh L, et al. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol
2019;25:3704-21.
46. Aravinthan AD, Bruni SG, Doyle AC, et al. Liver transplantation is a preferable alternative to palliative therapy for selected patients with
advanced hepatocellular carcinoma. Ann Surg Oncol 2017;24:1843-51.
47. Jeong Y, Shin MH, Yoon SM, et al. Liver transplantation after transarterial chemoembolization and radiotherapy for hepatocellular
carcinoma with vascular invasion. J Gastrointest Surg 2017;21:275-83.
48. Yoon YI, Lee SG. Living donor liver transplantation for hepatocellular carcinoma: an asian perspective. Dig Dis Sci 2019;64:993-1000.
49. Todo S, Furukawa H; Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with
hepatocellular carcinoma: experience in Japan. Ann Surg 2004;240:451-9.
50. Zhu XD, Li KS, Sun HC. Adjuvant therapies after curative treatments for hepatocellular carcinoma: current status and prospects. Genes
Dis 2020;7:359-69.
51. Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular
carcinoma: long-term outcomes and side effects. Transplantation 2007;83:1162-8.
52. Cholongitas E, Mamou C, Rodríguez-Castro KI, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of
hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int 2014;27:1039-49.
53. Geissler EK, Schnitzbauer AA, Zölke C, et al. Sirolimus use in liver transplant recipients with Hepatocellular carcinoma: a randomized,
Multicenter, open-label phase 3 Trial. Transplantation 2016;100:116-25.
54. Filgueira NA. Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentation. World J
Hepatol 2019;11:261-72.
55. Huang L, Li GM, Zhu JY, et al. Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the
Milan criteria: a preliminary study. Onco Targets Ther 2012;5:457-62.
56. Satapathy SK, Das K, Kocak M, et al. No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced
hepatocellular carcinoma on explant. Clin Transplant 2018;32:e13246.
57. Noda S, Hira D, Osaki R, et al. Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: